Investigation of p53 codon 72 polymorphism in patients with acute myeloid leukemia in Iran

A common polymorphism at codon 72 in the p53 gene has been associated with the increased risk for lung, oral, prostate, breast and colorectal cancers. We studied this polymorphism in acute myeloid leukemia specimen from Alzahra Hospital in Isfahan city. In the present case-control study, 59 whole blood specimen from normal people and 59 acutemyeloid leukemia specimen were analyzed. p53 codon 72 genotypes were identified using allele-specificPCR. Chi-square test was used for the comparison of the frequency distribution of three genotypes of codon 72 in cases and control specimen. Resulting PCR products were either 177bp for proline allele or 141bp for arginine allele. The genotype distribution for p53 polymorphism showed 11.9%, 81.4%, and 6.8% for the Arg/Arg, Arg/Pro, and Pro/Pro genotypes in control samples and 33.9%, 61%, and 5.1% in acute myeloid leukemia specimen, respectively. The differences in the distribution of p53 codon 72 polymorphism between the cases and controls were statistically significant (p = 0.04). Deferasirox is relatively more effective than deferoxamine in reducing iron content of the liver and heart. Moreover, deferasirox is more effective in reducing cardiac iron content relative to liver iron content.